Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients - Ghiringhelli, F; Menard, C; Puig, P E; Ladoire, S; Roux, S; Martin, F; Solary, E; Le Cesne, A; Zitvogel, L; Chauffert, B (Cancer Immunol Immunother, 2007)